These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 29400014)

  • 1. Is repeated high-dose medroxyprogesterone acetate (MPA) therapy permissible for patients with early stage endometrial cancer or atypical endometrial hyperplasia who desire preserving fertility?
    Yamagami W; Susumu N; Makabe T; Sakai K; Nomura H; Kataoka F; Hirasawa A; Banno K; Aoki D
    J Gynecol Oncol; 2018 Mar; 29(2):e21. PubMed ID: 29400014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of medroxyprogesterone acetate treatment and retreatment for atypical endometrial hyperplasia and endometrial cancer.
    Tamauchi S; Kajiyama H; Utsumi F; Suzuki S; Niimi K; Sakata J; Mizuno M; Shibata K; Kikkawa F
    J Obstet Gynaecol Res; 2018 Jan; 44(1):151-156. PubMed ID: 29121428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on the oncologic and obstetric outcomes of medroxyprogesterone acetate treatment for atypical endometrial hyperplasia and endometrial cancer.
    Tamauchi S; Nakagawa A; Yoshida K; Yoshihara M; Yokoi A; Yoshikawa N; Niimi K; Kajiyama H
    J Obstet Gynaecol Res; 2024 Sep; 50(9):1614-1621. PubMed ID: 39092804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Live births and maintenance with levonorgestrel IUD improve disease-free survival after fertility-sparing treatment of atypical hyperplasia and early endometrial cancer.
    Novikova OV; Nosov VB; Panov VA; Novikova EG; Krasnopolskaya KV; Andreeva YY; Shevchuk AS
    Gynecol Oncol; 2021 Apr; 161(1):152-159. PubMed ID: 33461741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer.
    Mitsuhashi A; Sato Y; Kiyokawa T; Koshizaka M; Hanaoka H; Shozu M
    Ann Oncol; 2016 Feb; 27(2):262-6. PubMed ID: 26578736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors affecting pregnancy outcomes in young women treated with fertility-preserving therapy for well-differentiated endometrial cancer or atypical endometrial hyperplasia.
    Inoue O; Hamatani T; Susumu N; Yamagami W; Ogawa S; Takemoto T; Hirasawa A; Banno K; Kuji N; Tanaka M; Aoki D
    Reprod Biol Endocrinol; 2016 Jan; 14():2. PubMed ID: 26769300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II trial evaluating the efficacy and safety of repeated high dose medroxyprogesterone acetate (MPA) therapy for patients with recurrent early-stage endometrial cancer or atypical endometrial hyperplasia: Japanese Gynecologic Oncology Group study (JGOG2051/KGOG2031, REMPA trial).
    Sakai K; Yamagami W; Sato Y; Susumu N; Yokoyama Y; Takehara K; Mandai M; Okamoto A
    J Gynecol Oncol; 2024 Nov; 35(6):e106. PubMed ID: 38789396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncologic and obstetrical outcomes after fertility-preserving retreatment in patients with recurrent atypical endometrial hyperplasia and endometrial cancer.
    He Y; Wang Y; Zhou R; Wang J
    Int J Gynecol Cancer; 2020 Dec; 30(12):1902-1907. PubMed ID: 33051245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Analysis of pregnancy outcome after fertility-preserving treatment among women with atypical endometrial hyperplasia or endometrial carcinoma].
    Xiao ZR; Lu Q; Zhou R; Wang YQ; Liang WY; Liu HX; Tang HR; Wu GZ; Liu XS; Zhang H; Ren Y; Wang JL
    Zhonghua Fu Chan Ke Za Zhi; 2020 Dec; 55(12):857-864. PubMed ID: 33355761
    [No Abstract]   [Full Text] [Related]  

  • 10. Hysteroscopic Endometrial Focal Resection followed by Levonorgestrel Intrauterine Device Insertion as a Fertility-Sparing Treatment of Atypical Endometrial Hyperplasia and Early Endometrial Cancer: A Retrospective Study.
    Giampaolino P; Di Spiezio Sardo A; Mollo A; Raffone A; Travaglino A; Boccellino A; Zizolfi B; Insabato L; Zullo F; De Placido G; Bifulco G
    J Minim Invasive Gynecol; 2019; 26(4):648-656. PubMed ID: 30017893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncologic and reproductive outcomes after fertility-sparing management with oral progestin for women with complex endometrial hyperplasia and endometrial cancer.
    Chen M; Jin Y; Li Y; Bi Y; Shan Y; Pan L
    Int J Gynaecol Obstet; 2016 Jan; 132(1):34-8. PubMed ID: 26493012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncologic, fertility, and obstetric outcomes with MPA therapy in women with endometrial cancer and atypical endometrial hyperplasia.
    Takeda A; Yamamoto Y; Tamura K; Aoki H; Noguchi H; Minato S; Kamada S; Arakaki R; Kaji T; Iwasa T
    J Obstet Gynaecol Res; 2024 Apr; 50(4):633-638. PubMed ID: 38154145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metformin plus megestrol acetate compared with megestrol acetate alone as fertility-sparing treatment in patients with atypical endometrial hyperplasia and well-differentiated endometrial cancer: a randomised controlled trial.
    Yang BY; Gulinazi Y; Du Y; Ning CC; Cheng YL; Shan WW; Luo XZ; Zhang HW; Zhu Q; Ma FH; Liu J; Sun L; Yu M; Guan J; Chen XJ
    BJOG; 2020 Jun; 127(7):848-857. PubMed ID: 31961463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognosis of patients with endometrial cancer or atypical endometrial hyperplasia after complete remission with fertility-sparing therapy.
    Ga H; Taguchi A; Honjoh H; Nishijima A; Eguchi S; Miyamoto Y; Sone K; Mori M; Osuga Y
    Arch Gynecol Obstet; 2023 Nov; 308(5):1629-1634. PubMed ID: 37310452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fertility-sparing re-treatment for endometrial cancer and atypical endometrial hyperplasia patients with progestin-resistance: a retrospective analysis of 61 cases.
    Chen J; Cao D
    World J Surg Oncol; 2024 Jun; 22(1):169. PubMed ID: 38918837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacies and pregnant outcomes of fertility-sparing treatment with medroxyprogesterone acetate for endometrioid adenocarcinoma and complex atypical hyperplasia: our experience and a review of the literature.
    Ohyagi-Hara C; Sawada K; Aki I; Mabuchi S; Kobayashi E; Ueda Y; Yoshino K; Fujita M; Tsutsui T; Kimura T
    Arch Gynecol Obstet; 2015 Jan; 291(1):151-7. PubMed ID: 25118836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical outcomes analysis of fertility-preserving therapy for atypical endometrial hyperplasia and early endometrial carcinoma].
    He YJ; Wang YQ; Dai YB; Zhou R; Lu Q; Liu GL; Wang JL
    Zhonghua Zhong Liu Za Zhi; 2022 Mar; 44(3):291-296. PubMed ID: 35316880
    [No Abstract]   [Full Text] [Related]  

  • 18. GnRH-a-based fertility-sparing treatment of atypical endometrial hyperplasia (AEH) and early endometrial carcinoma (EC) patients: a multicenter, open-label, randomized designed clinical trial protocol.
    Liu Q; Zhou H; Yu M; Cao D; Yang J
    Trials; 2024 Sep; 25(1):578. PubMed ID: 39223633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medroxyprogesterone acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and endometrial carcinoma: trial protocol for a prospective, randomised, open, blinded-endpoint design, dose-response trial (FELICIA trial).
    Mitsuhashi A; Kawasaki Y; Hori M; Fujiwara T; Hanaoka H; Shozu M
    BMJ Open; 2020 Feb; 10(2):e035416. PubMed ID: 32114477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progestin intrauterine device and GnRH analogue for uterus-sparing treatment of endometrial precancers and well-differentiated early endometrial carcinoma in young women.
    Minig L; Franchi D; Boveri S; Casadio C; Bocciolone L; Sideri M
    Ann Oncol; 2011 Mar; 22(3):643-649. PubMed ID: 20876910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.